TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03677336

Intervention type: DRUG
Group type: OTHER
Intervention: Dydrogesterone Oral Tablet
Description: Tablet, oral, 10 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days

Intervention type: DRUG
Group type: OTHER
Intervention: Dydrogesterone Oral Tablet
Description: Tablet, oral, 10 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days

Intervention type: DRUG
Group type: OTHER
Intervention: Micronized progesterone
Description: Capsule, vaginal, 200 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days

Intervention type: DRUG
Group type: OTHER
Intervention: Micronized progesterone
Description: Capsule, vaginal, 200 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Dydrogesterone oral tablet
Description: Tablet, indistinguishable from dydrogesterone oral tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Dydrogesterone oral tablet
Description: Tablet, indistinguishable from dydrogesterone oral tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Micronized progesterone
Description: Capsule, indistinguishable from micronized vaginal progesterone capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Micronized progesterone
Description: Capsule, indistinguishable from micronized vaginal progesterone capsules
Study: NCT01872637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Multi-Component Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study: NCT00675155

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Far Infrared Radiation
Description: Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
Study: NCT02379559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: For the first 12-weeks, participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise. Exercise duration will increase from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, men will maintain 150 min/wk of moderate-intensity physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: We will provide weekly healthy lifestyle tips via text messages, and will include tips such as managing stressors in life and getting better sleep.
Study: NCT03607825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurapheresis System
Description: CSF filtration system and lumbar catheter
Study: NCT03311425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Application of 40mg Depomedrol (methylprednisolone acetate) suspension into the retropharyngeal space prior to incision closure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Administration of 10mg Dexamethasone IV intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Administration of 10mg Dexamethasone IV intraoperatively
Study: NCT00885963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapacitabine
Description: twice daily by mouth for 7 days or once daily by mouth for 5 days/week x 2 weeks every 21 days
Study: NCT03542097

Intervention type: OTHER
Intervention: MGMT methylation evaluation
Description: The MGMT methylation will be evaluated by extracting DNA from fresh and Formalin Fixed paraffin Embedded (FFPE) tumor samples
Study: NCT02352363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301

Intervention type: OTHER
Group type: OTHER
Intervention: Observational cohort
Study: NCT03704532

Intervention type: PROCEDURE
Intervention: Operative treatment
Description: Open surgical repair of tendon rupture

Intervention type: PROCEDURE
Intervention: Nonoperative treatment
Description: Nonoperative treatment with lower leg orthosis and functional rehabilitation
Study: NCT03193671

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: Improving diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: Improving diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: Improving diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: Improving diagnosis
Study: NCT00345384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine titrated over 24 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal Saline)
Study: NCT05016414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure
Description: lower body negative pressure at -20mmHg delivered via a custom designed sleeping sack
Study: NCT03809884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counselling
Description: Individually tailored strategy to increase potassium in the diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Counselling
Description: Individually tailored strategy to increase potassium in the diet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Citrate
Description: Dosing of 50 to 100 mmol of potassium citrate per day (as 25 to 50 ml of the liquid solution).
Study: NCT03719365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVAPSV
Description: During the first trial, PSV will be set in order to obtain a Vt between 6 and 8 ml/kg; this support level will be defined as PSV100. Subsequently, the corresponding NAVA level (NAVA 100) will be determined using a dedicated ventilator function (NAVA Preview) which is able to estimate NAVA level in order to deliver an equivalent inspiratory peak pressure (Paw peak) compared to that obtained during PSV mode. Afterwards, PSV100 and NAVA100 will be first increased (PSV150 and NAVA150) during the second trial and then decreased during the third trial (PSV50 and NAVA150) by 50% from basal value. During the study period, PEEP and FiO2 will be kept equal to the values in use before patient enrollment.
Study: NCT01502995

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser light (U-Step Walking Stabilizer with laser light)
Description: Use of a laser light on a rolling walker during episodes of freezing of gait.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser light (U-Step Walking Stabilizer with laser light)
Description: Use of a laser light on a rolling walker during episodes of freezing of gait.
Study: NCT03290157

Intervention type: DEVICE
Group type: OTHER
Intervention: ColoprAPP
Description: Additional downloaded SPA for reminding the crucial steps of colonoscopy preparation
Study: NCT00852826

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard axillary lymphadenectomy
Description: Standard axillary lymphadenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen sponge coated with human coagulation factors
Description: Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
Study: NCT04586777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transvertebral direct current stimulation (tvDCS)
Description: tvDCS is a painless, non-invasive form of spinal stimulation which delivers safe, low levels of electrical current to the spinal cord through the back. It is believed to be able to influence the excitability of the brain and spinal cord.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transvertebral direct current stimulation (tvDCS)
Description: tvDCS is a painless, non-invasive form of spinal stimulation which delivers safe, low levels of electrical current to the spinal cord through the back. It is believed to be able to influence the excitability of the brain and spinal cord.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transvertebral direct current stimulation (tvDCS)
Description: tvDCS is a painless, non-invasive form of spinal stimulation which delivers safe, low levels of electrical current to the spinal cord through the back. It is believed to be able to influence the excitability of the brain and spinal cord.
Study: NCT03142542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYDENA TAB.75mg(Udenafil 75mg)
Description: ZYDENA TAB.75mg(Udenafil 75mg): by mouth, Once daily, for 32 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet: by mouth, Once daily, for 32 weeks
Study: NCT04410016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Staff Wellbeing Centres
Description: 2 Centres (rooms) accessible to staff for rest and relaxation, work breaks, supports advice and signposting. They are manned by support workers called Wellbeing Buddies.
Study: NCT02413385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealtheSteps Program
Description: 6-month evidence-based lifestyle Rx program: At set time points over the 6-month period, participants have in-person visits with a HeS coach at the clinic setting. At each in-person session, the participant receives an individualized Rx for exercise, physical activity (step count) and healthy eating. The HeS Coach and participant then engage in a coaching/goal setting conversation to set detailed plans and goals to achieve their prescriptions. Participants independently choose which activities they will take part in to achieve their lifestyle Rx's and goals. In between in-person sessions, the participants have access to a suite of free-of-charge health technology support tools to: a) track their exercise, physical activity, and healthy eating; and b) receive virtual coaching and support.
Study: NCT03145961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg intravenous infusion
Study: NCT03075891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 1% cream
Description: Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivermectin 1% cream
Description: Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules
Description: 1 Capsule once-daily for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo capsules
Description: 1 Capsule once-daily for 12 weeks
Study: NCT04264390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement-to-music
Description: Movement-to-music is a physical activity program that was developed onsite at a state-of-the-art adapted fitness facility. The program includes movements that are coupled with music to enhance muscular strength, cardiorespiratory capacity, flexibility, and balance. For this study, the program will be packaged into playlists of exercise videos that will be given to participants. Participants will be instructed to complete the prescribed videos 3 times per week. Participants will also be asked to attend 4 behavioral coaching calls with a telecoach. The goals of the behavioral coaching calls will be to address issues with the technology components of the program and promote physical activity participation within the community and adherence to the movement-to-music videos.
Study: NCT02686866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bioelectrical impedance analysis (Bodystat, Quadscan 4000)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dual-energy X-ray absorptiometry (Hologic, Delphi QDR)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hand grip strength
Study: NCT01388244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening
Description: Screening by risk factor assessment (FRAX) followed by DXA

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Observation by use of register data
Study: NCT03108586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental treatment
Description: Dental treatment of all dental needs present in adults related or not to the dental caries

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental treatment
Description: Dental treatment of all dental needs present in adults related or not to the dental caries
Study: NCT02819180

Intervention type: BIOLOGICAL
Intervention: Butantan Influenza Trivalent, Fragmented and Inactivated vaccine

Intervention type: BIOLOGICAL
Intervention: Butantan Influenza Trivalent, Fragmented and Inactivated vaccine
Study: NCT04097405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-0120
Description: Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120
Description: Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
Study: NCT00954512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT01346514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Addiction/Housing Case Management
Description: AHCM provided: 1) support in obtaining/maintaining housing through education about resources, coordination with VA and community housing program providers, assistance in establishing housing program eligibility, and problem-solving around threats to housing stability; 2) support for SUD and related issues that affect housing status through treatment engagement/re-engagement, referrals for needed services (e.g. psychiatric, medical, vocational), and addressing substance use issues proactively; 3) promotion of residential stability through Life Skills Training, which was designed to improve key skills (room and self-care, money management, and community participation).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Housing Support Group
Description: The HSG focused on gaining support from fellow study participants and learning from those who successfully obtained housing. Group facilitators provided education about housing resources and assistance with housing-related issues.
Study: NCT02168790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amniotic membrane ring
Description: The amniotic membrane ring system (AmnioClip) is device for sutureless application of amniotic membrane to oculare surfaces. Amniotic membrane is mounted between the two rings with a specially designed, accessory mounting device.
Study: NCT01097486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoFuse
Description: Single Dose NeoFuse Surgical Implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allograft
Description: Single Dose Allograft Surgical Implantation
Study: NCT01492491

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SUPRA-HFR
Description: usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen.
Study: NCT04180241

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: POEM
Description: Peroral endoscopic myotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: POEM
Description: Peroral endoscopic myotomy
Study: NCT00954512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Study: NCT01754883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: Oral Lithium carbonate to target serum levle of 0.6-0.8.
Study: NCT01959191

Intervention type: DRUG
Intervention: Dual antiplatelet therapy including aspirin and clopidogrel after off-pump coronary bypass surgery
Description: aspirin 100mg/day and clopidogrel 75mg/day, PO, from the day of surgery for 1 year

Intervention type: DRUG
Intervention: Dual antiplatelet therapy including aspirin and clopidogrel after off-pump coronary bypass surgery
Description: aspirin 100mg/day and clopidogrel 75mg/day, PO, from the day of surgery for 1 year
Study: NCT04775121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterium Glucose
Description: Oral administration of 20 g Deuterium Glucose on a 3-hour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterium Glucose
Description: Oral administration of 20 g Deuterium Glucose on a 3-hour
Study: NCT04813601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATLAS 2030
Description: The participant will attend the laboratory every week, two days a week. The therapy will consist of the use of the exoskeleton for rehabilitative purposes. At the end of each three-month period, each patient's data will be monitored.
Study: NCT00258180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Administered IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Administered IV over 1 hour on days 1-4
Study: NCT02826590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck passive mobilizations
Description: Passive mobilizations performed to the neck of the participant by a Physiotherapist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Manual contact
Description: Manual contact applied to the neck of the participant by a Physiotherapist
Study: NCT02435472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This open-label, two-arm randomized controlled trial (RCT) will investigate the effects of 16 weeks of structured aerobic training, relative to usual care (print material with physical activity guidance) in 76 men with histologically confirmed low-risk prostate adenocarcinoma on active surveillance. The only investigational therapeutic agent being tested in this trial is a behavioral intervention in the form of aerobic training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: This open-label, two-arm randomized controlled trial (RCT) will investigate the effects of 16 weeks of structured aerobic training, relative to usual care (print material with physical activity guidance) in 76 men with histologically confirmed low-risk prostate adenocarcinoma on active surveillance. The only investigational therapeutic agent being tested in this trial is a behavioral intervention in the form of aerobic training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Test (CPET)
Description: Exercise capacity test to assess peak oxygen consumption (VO2peak)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Test (CPET)
Description: Exercise capacity test to assess peak oxygen consumption (VO2peak)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Test (CPET)
Description: Exercise capacity test to assess peak oxygen consumption (VO2peak)
Study: NCT01516411

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Intervention for Lifestyle Eating/Exercise @ Stanford
Description: Participants are randomized to one of 4 groups, each of which uses a different Smartphone app to promote health behavior change

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Intervention for Lifestyle Eating/Exercise @ Stanford
Description: Participants are randomized to one of 4 groups, each of which uses a different Smartphone app to promote health behavior change

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Intervention for Lifestyle Eating/Exercise @ Stanford
Description: Participants are randomized to one of 4 groups, each of which uses a different Smartphone app to promote health behavior change

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Intervention for Lifestyle Eating/Exercise @ Stanford
Description: Participants are randomized to one of 4 groups, each of which uses a different Smartphone app to promote health behavior change
Study: NCT02238717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865 (65mg)
Description: single oral dose (65 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865 (15mg)
Description: single oral dose (15mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: single oral dose (300mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching oral placebo
Study: NCT01878123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMP-110
Description: Dose levels 1 through 7: Single intravenous infusion on Day 0

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose levels 4 through 7: Single intravenous infusion on Day 0
Study: NCT01141270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFOLIA
Description: single sc injection, 225 IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f
Description: single sc injection, 225IU
Study: NCT03517618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1+leucovorin
Description: Eligible patients will receive TS-1 orally 40-60 mg (depending on patient's body surface area (BSA)) in combination with calcium folinate 30 mg twice a day for 7 days in a 2-week cycle.~The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study.
Study: NCT00710372

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT006-AngQb
Description: s.c. injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CYT006-AngQb
Description: s.c. injection
Study: NCT02218840

Intervention type: OTHER
Intervention: Smoking topography
Description: Evaluation of cigar smoking topography
Study: NCT01566929

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie diet treatment
Description: Reduction of calorie intake to only 800 kcal/day by using LCD during 12 weeks